Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report

Anat R. Tambur, Patricia Campbell, Frans H. Claas, Sandy Feng, Howard M. Gebel, Annette M. Jackson, Roslyn B. Mannon, Elaine F. Reed, Kathryn Tinckam, Medhat Askar, Anil Chandraker, Patricia P. Chang, Monica Colvin, Anthony Jake Demetris, Joshua M. Diamond, Anne I. Dipchand, Robert L. Fairchild, Mandy L. Ford, John Friedewald, Ronald G. GillDenis Glotz, Hilary Goldberg, Ramsey Hachem, Stuart Knechtle, Jon Kobashigawa, Deborah J. Levine, Joshua Levitsky, Michael Mengel, Edgar Milford, Kenneth A. Newell, Jacqueline G. O’Leary, Scott Palmer, Parmjeet Randhawa, John Smith, Laurie Snyder, Randall C. Starling, Stuart Sweet, Timucin Taner, Craig J. Taylor, Steve Woodle, Adriana Zeevi, Peter Nickerson

Research output: Contribution to journalArticlepeer-review

91 Scopus citations


The presence of preexisting (memory) or de novo donor-specific HLA antibodies (DSAs) is a known barrier to successful long-term organ transplantation. Yet, despite the fact that laboratory tools and our understanding of histocompatibility have advanced significantly in recent years, the criteria to define presence of a DSA and assign a level of risk for a given DSA vary markedly between centers. A collaborative effort between the American Society for Histocompatibility and Immunogenetics and the American Society of Transplantation provided the logistical support for generating a dedicated multidisciplinary working group, which included experts in histocompatibility as well as kidney, liver, heart, and lung transplantation. The goals were to perform a critical review of biologically driven, state-of-the-art, clinical diagnostics literature and to provide clinical practice recommendations based on expert assessment of quality and strength of evidence. The results of the Sensitization in Transplantation: Assessment of Risk (STAR) meeting are summarized here, providing recommendations on the definition and utilization of HLA diagnostic testing, and a framework for clinical assessment of risk for a memory or a primary alloimmune response. The definitions, recommendations, risk framework, and highlighted gaps in knowledge are intended to spur research that will inform the next STAR Working Group meeting in 2019.

Original languageEnglish (US)
Pages (from-to)1604-1614
Number of pages11
JournalAmerican Journal of Transplantation
Issue number7
StatePublished - Jul 2018


  • alloantibody
  • clinical research/practice
  • clinical trial design
  • guidelines
  • histocompatibility
  • immunobiology
  • monitoring: immune
  • sensitization

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)


Dive into the research topics of 'Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report'. Together they form a unique fingerprint.

Cite this